Literature DB >> 27601215

Application of The Paris System to atypical urine cytology samples: correlation with histology and UroVysion® FISH.

Y Miki1, M Neat2, A Chandra1.   

Abstract

OBJECTIVES: To evaluate whether atypical urine cytology cases may be stratified more objectively using The Paris System (TPS) and whether reclassified cases correlate with histology and UroVysion® results.
METHODS: Atypical urine cytology cases subjected to UroVysion® testing over a period of 6 years were reviewed. Each case was reclassified according to TPS and correlated with histology and UroVysion® results.
RESULTS: A total of 91 cases were identified; 70.3% were reclassified as 'negative for high-grade urothelial carcinoma (HGUC)' and 14.3% as 'atypical urothelial cells (AUC)'. The histological correlation was available in 45 cases. In the 'negative for HGUC' category, 67.9% had no histological evidence of malignancy, but 17.9% were diagnosed as HGUC. In the 'AUC' category, histology revealed urothelial carcinoma in 70% of the cases (of these, 71.4% were high grade). There was no histological evidence of malignancy in 30% of cases; notably, all of which were from patients under surveillance. The sensitivity and specificity of UroVysion® were 85.7% and 33.3% in the 'AUC' group and 62.5% and 100% in the 'negative for HGUC' group.
CONCLUSIONS: The Paris System is an objective template for reporting urine cytology specimens, and is particularly useful in identifying HGUC cases and refining the category of 'AUC'.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  The Paris System; UroVysion®; atypical urothelial cells; urine cytology

Mesh:

Year:  2016        PMID: 27601215     DOI: 10.1111/cyt.12367

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  7 in total

1.  Fluorescence Emitted by Papanicolaou-Stained Urothelial Cells Improves Sensitivity of Urinary Conventional Cytology for Detection of Urothelial Tumors.

Authors:  Kinan Drak Alsibai; Ghislaine Daste; Sophie Ferlicot; Monique Fabre; Karine Steenkeste; Julia Salleron; Yacine Hammoudi; Marie-Pierre Fontaine-Aupart; Pascal Eschwege
Journal:  World J Oncol       Date:  2020-10-15

Review 2.  UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives.

Authors:  Takashi Nagai; Taku Naiki; Toshiki Etani; Keitaro Iida; Yusuke Noda; Nobuhiko Shimizu; Teruki Isobe; Satoshi Nozaki; Takehiko Okamura; Ryosuke Ando; Noriyasu Kawai; Takahiro Yasui
Journal:  Transl Androl Urol       Date:  2021-04

3.  Performance of the UroVysion® FISH assay for the diagnosis of malignant effusions using two cutoff strategies.

Authors:  Débora C B Rosolen; Daniel K Faria; Caroline S Faria; Leila Antonangelo
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

4.  A Quest for Accuracy: Evaluation of The Paris System in Diagnosis of Urothelial Carcinomas.

Authors:  Sharada Rai; Bhagat S Lali; Chaithra G Venkataramana; Cheryl S Philipose; Ranjitha Rao; Gg Laxman Prabhu
Journal:  J Cytol       Date:  2019 Jul-Sep       Impact factor: 1.000

5.  Impact of the Paris system for reporting urine cytopathology on predictive values of the equivocal diagnostic categories and interobserver agreement.

Authors:  Rania Bakkar; James Mirocha; Xuemo Fan; David P Frishberg; Mariza de Peralta-Venturina; Jing Zhai; Shikha Bose
Journal:  Cytojournal       Date:  2019-10-22       Impact factor: 2.091

6.  Comparison of Diagnostic Performances of Urine Cytology Before and After the Use of The Paris System Criteria: An Institutional Experience from Turkey.

Authors:  Sevgen Onder; Olcay Kurtulan; Altan Kavuncuoglu; Bulent Akdogan
Journal:  J Cytol       Date:  2021-08-23       Impact factor: 1.000

Review 7.  The Paris System for Reporting Urinary Cytology: A Meta-Analysis.

Authors:  Ilias P Nikas; Svenja Seide; Tanja Proctor; Zoi Kleinaki; Maria Kleinaki; Jordan P Reynolds
Journal:  J Pers Med       Date:  2022-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.